What is HC Wainwright’s Estimate for ONCY FY2030 Earnings?

Oncolytics Biotech Inc. (NASDAQ:ONCY) – HC Wainwright reduced their FY2030 earnings per share (EPS) estimates for shares of Oncolytics Biotech in a research note issued on Tuesday, May 26th. HC Wainwright analyst P. Trucchio now anticipates that the company will post earnings of $0.14 per share for the year, down from their previous estimate of $0.18. HC Wainwright has a “Buy” rating and a $10.00 price objective on the stock. The consensus estimate for Oncolytics Biotech’s current full-year earnings is ($0.20) per share.

A number of other research firms also recently weighed in on ONCY. Wall Street Zen downgraded Oncolytics Biotech from a “hold” rating to a “sell” rating in a research note on Saturday, May 16th. Weiss Ratings raised Oncolytics Biotech from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Friday, May 8th. One investment analyst has rated the stock with a Strong Buy rating, two have given a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $8.50.

Oncolytics Biotech Trading Up 0.1%

Shares of NASDAQ:ONCY opened at $0.81 on Wednesday. The business has a 50-day moving average price of $0.94 and a two-hundred day moving average price of $0.98. The stock has a market capitalization of $96.71 million, a P/E ratio of -2.61 and a beta of 1.02. Oncolytics Biotech has a 1-year low of $0.33 and a 1-year high of $1.51.

Oncolytics Biotech (NASDAQ:ONCY) last announced its quarterly earnings data on Thursday, May 14th. The company reported ($0.08) earnings per share for the quarter, missing the consensus estimate of ($0.05) by ($0.03).

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of the company. Scientech Research LLC bought a new position in Oncolytics Biotech during the 3rd quarter worth approximately $25,000. PFG Investments LLC boosted its stake in Oncolytics Biotech by 131.0% during the 1st quarter. PFG Investments LLC now owns 52,900 shares of the company’s stock worth $45,000 after acquiring an additional 30,000 shares during the last quarter. Blair William & Co. IL bought a new position in Oncolytics Biotech during the 4th quarter worth approximately $28,000. Security National Bank of Sioux City Iowa IA bought a new position in Oncolytics Biotech during the 4th quarter worth approximately $29,000. Finally, Ground Swell Capital LLC bought a new position in Oncolytics Biotech during the 4th quarter worth approximately $30,000. Institutional investors own 6.82% of the company’s stock.

About Oncolytics Biotech

Oncolytics Biotech Inc (NASDAQ: ONCY) is a clinical-stage biotechnology company focused on the development of novel oncolytic viral therapies for the treatment of cancer. The company’s lead investigational agent, pelareorep (Reolysin), is a proprietary formulation of reovirus engineered to selectively infect and destroy tumor cells while stimulating a systemic antitumor immune response. Oncolytics leverages the natural biology of the virus to enhance the activity of standard?of?care treatments and immune checkpoint inhibitors.

Pelareorep has progressed into multiple advanced clinical trials, with combination studies conducted in metastatic breast cancer, non?small cell lung cancer and head and neck cancers.